We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Medical News & Perspectives |

Advances Reshaping Sickle Cell Therapy

M. J. Friedrich
JAMA. 2011;305(3):239-242. doi:10.1001/jama.2010.1929.
Text Size: A A A
Published online


In 1910, James Herrick, MD, an attending physician at Presbyterian Hospital and professor of medicine at Rush Medical College in Chicago, published the first case report of sickle cell disease (SCD), describing the “peculiar elongated and sickle-shaped” red blood cells from an anemic dental student from Grenada (Herrick J. Arch Intern Med. 1910;6:517-521).

Since that observation was made 100 years ago, the disorder named for these cells has become one of the best understood diseases at the cellular and genomic levels, leading the way for the scientific study of human genetics and molecular biology. And yet, as Susan Shurin, MD, acting director of the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda, Md, pointed out, the most effective treatments for SCD—antibiotics, blood transfusion, hydroxyurea, and blood and marrow stem cell transplant—have been imported from the treatment of other conditions.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Scientists are seeking more targeted and tailored therapies for sickle cell disease, which results from a mutation that gives hemoglobin molecules a propensity to link together and cause red blood cells to develop a sickle shape.

(Photo credit: Gopal Murti, MD/www.sciencesource.com)



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections